Binita Shah1, Gaurang Shah. 1. Binita Shah, Gaurang Shah, Department of Pharmacology, K B Institute of Pharmaceutical Education and Research, Gandhinagar 382023, Gujarat, India.
Abstract
AIM: To evaluate the effect of chronic thrombin inhibition by heparin on experimentally induced chronic liver injury (liver fibrosis) in rats. METHODS: Chronic liver injury (liver fibrosis) was induced in Wistar rats by oral administration of carbon tetrachloride (CCl4) for 7 wk, an animal model with persistent severe hepatic fibrosis. Intravenous administration of the thrombin antagonist (heparin) started 1 wk after the start of CCl4 intoxication for 6 wk. After completion of treatment (7 wk), markers of hepatic dysfunction were measured and changes evaluated histopathologically. RESULTS: Higher serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase (ALP), total, direct and indirect bilirubin levels, as well as lower fibrinogen levels, were found in CCl4 intoxicated rats. Heparin, silymarin and combination of drug (heparin and silymarin) treatment for 6 wk prevented a rise in SGOT, SGPT, ALP, total, direct and indirect bilirubin levels and improved fibrinogen levels. Deterioration in hepatic function determined by the fibrosis area was retarded, as evident from hepatic histopathology. Total protein levels were not changed in all groups. CONCLUSION: Heparin, a thrombin antagonist, preserved hepatic function and reduced severity of hepatic dysfunction/fibrogenesis. Combination of heparin and silymarin produced additional benefits on liver fibrosis.
AIM: To evaluate the effect of chronic thrombin inhibition by heparin on experimentally induced chronic liver injury (liver fibrosis) in rats. METHODS:Chronic liver injury (liver fibrosis) was induced in Wistar rats by oral administration of carbon tetrachloride (CCl4) for 7 wk, an animal model with persistent severe hepatic fibrosis. Intravenous administration of the thrombin antagonist (heparin) started 1 wk after the start of CCl4 intoxication for 6 wk. After completion of treatment (7 wk), markers of hepatic dysfunction were measured and changes evaluated histopathologically. RESULTS: Higher serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase (ALP), total, direct and indirect bilirubin levels, as well as lower fibrinogen levels, were found in CCl4 intoxicated rats. Heparin, silymarin and combination of drug (heparin and silymarin) treatment for 6 wk prevented a rise in SGOT, SGPT, ALP, total, direct and indirect bilirubin levels and improved fibrinogen levels. Deterioration in hepatic function determined by the fibrosis area was retarded, as evident from hepatic histopathology. Total protein levels were not changed in all groups. CONCLUSION:Heparin, a thrombin antagonist, preserved hepatic function and reduced severity of hepatic dysfunction/fibrogenesis. Combination of heparin and silymarin produced additional benefits on liver fibrosis.
Authors: N Hattori; J L Degen; T H Sisson; H Liu; B B Moore; R G Pandrangi; R H Simon; A F Drew Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: D C Howell; N R Goldsack; R P Marshall; R J McAnulty; R Starke; G Purdy; G J Laurent; R C Chambers Journal: Am J Pathol Date: 2001-10 Impact factor: 4.307
Authors: G Shivaraj; B Desai Prakash; V Sonal; K Shruthi; H Vinayak; M Avinash Journal: Eur Rev Med Pharmacol Sci Date: 2009 Sep-Oct Impact factor: 3.507
Authors: Mi Na Gil; Du Ri Choi; Kwang Sik Yu; Ji Heun Jeong; Dong-Ho Bak; Do-Kyung Kim; Nam-Seob Lee; Je-Hun Lee; Young-Gil Jeong; Chun Soo Na; Dae Seung Na; Ki-Hyun Ryu; Seung Yun Han Journal: Anat Cell Biol Date: 2016-09-29
Authors: José Ignacio Fortea; Ángela Puente; Antonio Cuadrado; Patricia Huelin; Raúl Pellón; Francisco José González Sánchez; Marta Mayorga; María Luisa Cagigal; Inés García Carrera; Marina Cobreros; Javier Crespo; Emilio Fábrega Journal: Int J Mol Sci Date: 2020-12-10 Impact factor: 5.923